HPV 015: A Phase III, Double-blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/ASO4 Vaccine Administered Intramuscularly According to a Three-Dose Schedule (0, 1, 6 month) in Healthy Adult Female Subjects aged 26 years and above.
Investigator: Nahida Chakhtoura
Institutional Protocol #: 20057595
National Clinical Trials Identifier: NCT00456807
Division: Obstetrics and Gynecology
Therapeutic Area: Other
Enrolling Since: 3/20/2006